NEW YORK, Nov. 5-AnVil and Genomics Collaborative will work together to develop new products and resources for the life sciences market, AnVil said today.
Using its informatics and data visualization capabilities, AnVil will analyze cardiovascular clinical data from GCI's database. The two companies will build predictive and analytic models for coronary artery disease, myocardial infarction, hyperlipidemia and hypertension.
From this collaboration, the companies hope to develop products that will be useful to pharmaceutical and biotech companies in cardiovascular drug development. They will jointly develop a marketing and business plan.
AnVil is a data management and visualization company based in Burlington, Mass.
The two companies struck a deal to develop drugs for rheumatoid arthritis in April 2002.